Pollen Allergy Market Analysis Report 2025: Innovative Strategies in Pollen Allergy Diagnosis and Treatment Emerge - Global Forecast to 2030
This comprehensive report delivers insights into market trends, drivers, and forecasts, covering recent tariff developments affecting the industry. Pollen allergies, increasingly prevalent worldwide, are exacerbated by urbanization, climate change, and pollution. Advances in diagnosis and treatment, including molecular diagnostics and allergen immunotherapy, are shaping the market. With regions like Asia-Pacific driving growth due to healthcare investments, the report explores comprehensive market analysis, competitive landscapes, emerging trends, and regional dynamics, guiding strategic business decisions.
Pollen Allergy Market
Dublin, June 03, 2025 (GLOBE NEWSWIRE) -- The "Pollen Allergy - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Pollen Allergy was valued at US$5.4 Billion in 2024 and is projected to reach US$6.7 Billion by 2030, growing at a CAGR of 3.8% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Pollen Allergy market.
Global Pollen Allergy Market - Key Trends & Drivers SummarizedWhy Is Pollen Allergy Emerging as a Global Public Health Concern?Pollen allergy, medically referred to as seasonal allergic rhinitis or hay fever, is becoming a widespread public health issue affecting hundreds of millions globally. Characterized by symptoms such as nasal congestion, sneezing, watery eyes, and respiratory discomfort, the condition results from hypersensitivity of the immune system to pollen from grasses, weeds, and trees. The growing prevalence of pollen-induced allergies is closely linked to urbanization, climate change, increased air pollution, and extended pollen seasons - factors that together intensify allergen exposure and severity.Urban areas are reporting higher allergy rates due to the "urban heat island" effect and the proliferation of allergenic plant species in landscaping. Moreover, industrial emissions and diesel particulates interact with pollen grains, increasing their allergenicity and aggravating symptoms in sensitive populations. This trend is not limited to developed countries - rising diagnosis rates in Asia-Pacific, Latin America, and parts of Africa highlight that pollen allergy is fast becoming a global epidemic, particularly among children, adolescents, and working-age adults who suffer significant quality-of-life disruptions and productivity losses.How Are Diagnosis and Therapeutic Strategies Evolving for Effective Symptom Management?The diagnosis of pollen allergy traditionally involves skin prick tests, blood IgE assays, and clinical history analysis. However, recent developments in molecular diagnostics now enable allergen component-resolved diagnostics (CRD), which offer precise identification of the specific proteins within pollen that trigger hypersensitivity reactions. CRD is helping to tailor immunotherapy approaches and minimize cross-reactivity, especially in poly-sensitized individuals reacting to multiple environmental allergens.Pharmacological management includes antihistamines, intranasal corticosteroids, leukotriene receptor antagonists, and decongestants, with growing interest in combination therapies for multi-symptom control. Allergen immunotherapy (AIT), administered either subcutaneously (SCIT) or sublingually (SLIT), remains the only long-term disease-modifying treatment. AIT desensitizes the immune system through controlled allergen exposure and is gaining popularity due to its potential to prevent the progression of allergic rhinitis to asthma. Over-the-counter (OTC) allergy remedies, air filtration devices, and mobile health apps for pollen forecasting are further supporting symptom avoidance and self-management among patients worldwide.Where Is Innovation Taking Shape Across Diagnostics, Delivery Formats, and Regional Care Models?Innovation in the pollen allergy market is not confined to pharmaceuticals but spans across diagnostics, delivery systems, and digital therapeutics. Needle-free delivery devices for immunotherapy and metered-dose nasal sprays are enhancing patient adherence and reducing discomfort. Biotech firms are developing hypoallergenic recombinant pollen allergens and adjuvant-enhanced immunotherapy formulations for improved efficacy and reduced adverse reactions. These technologies are creating a shift toward personalized allergy care, especially in high-income markets.Digitally enabled care models are also gaining ground. Wearable air quality sensors, smartphone apps integrated with pollen dispersion models, and teleconsultation services are empowering patients to anticipate triggers and access timely medical support. Regionally, Europe remains at the forefront in allergy research and treatment accessibility, while North America shows strong commercial uptake of OTC and immunotherapy products. Asia-Pacific is emerging as a high-potential market, driven by rising allergic disease awareness, urban air quality challenges, and increasing healthcare investments. Governments are initiating school and workplace screening programs to identify and manage allergy-prone populations more proactively.What's Driving the Accelerated Growth of the Global Pollen Allergy Market?The growth in the global pollen allergy market is driven by several factors, including the rising global incidence of allergic rhinitis, worsening air quality, and longer pollen seasons linked to climate change. Increasing environmental awareness, improved allergy diagnostics, and broader availability of OTC antihistamines and immunotherapy solutions are further contributing to market expansion. Healthcare systems are also recognizing the socioeconomic impact of allergic rhinitis, which leads to missed school days, absenteeism, and comorbidities like sinusitis and asthma.Technological advancements in allergy testing, predictive modeling, and digital health management are enhancing early diagnosis and sustained care. Pharmaceutical innovations in non-sedating antihistamines, nasal corticosteroid combinations, and biologics are improving symptom control and reducing patient dropout from long-term treatment regimens. With growing emphasis on preventive healthcare, environmental control measures, and personalized immunotherapy, the pollen allergy market is expected to witness robust growth, especially as climate change continues to alter allergen distribution patterns and intensify the global allergic disease burden.Report Scope
Report Features:
Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
Company Profiles: Coverage of players such as AbbVie Inc., Aimmune Therapeutics, Alcon Inc., ALK-Abello A/S, Allergopharma and more.
Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Key Insights:
Market Growth: Understand the significant growth trajectory of the Instruments segment, which is expected to reach US$4.4 Billion by 2030 with a CAGR of a 4.2%. The Consumables segment is also set to grow at 3.0% CAGR over the analysis period.
Regional Analysis: Gain insights into the U.S. market, valued at $1.5 Billion in 2024, and China, forecasted to grow at an impressive 7.0% CAGR to reach $1.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Segments
Product Type (Instruments, Consumables, Services)
Therapeutics Drug Class (Antihistamines, Decongestants, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors, Nasal Anticholinergics, Immunomodulators, Auto injectable Epinephrine, Immunotherapy)
Allergen Type (Food, Inhaled, Drug, Other Allergen Types)
End-Use (Diagnostic Laboratories, Hospitals, Other End-Uses)
Tariff Impact Analysis: Key Insights for 2025What's Included in This Edition:
Tariff-adjusted market forecasts by region and segment
Analysis of cost and supply chain implications by sourcing and trade exposure
Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
Finalized tariff impacts and new trade agreement effects
Updated projections reflecting global sourcing and cost shifts
Expanded country-specific coverage across the industry
Key Attributes:
Report Attribute
Details
No. of Pages
498
Forecast Period
2024 - 2030
Estimated Market Value (USD) in 2024
$5.4 Billion
Forecasted Market Value (USD) by 2030
$6.7 Billion
Compound Annual Growth Rate
3.8%
Regions Covered
Global
Key Topics Covered: MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Tariff Impact on Global Supply Chain Patterns
Pollen Allergy - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
MARKET TRENDS & DRIVERS
Rising Global Prevalence of Seasonal Allergic Rhinitis Spurs Growth in the Pollen Allergy Management Market
Expansion of Urbanization and Air Pollution Throws the Spotlight on Heightened Allergen Sensitization
Development of Non-Sedating Antihistamines and Long-Acting Therapies Enhances Daily Symptom Control
Growth in Immunotherapy and SLIT (Sublingual Immunotherapy) Adoption Expands Treatment Landscape
Innovation in Air Filtration, Pollen Barriers, and Nasal Sprays Drives Preventive Allergy Management
Increasing Demand for OTC Remedies and Natural Allergy Relief Products Fuels Consumer Healthcare Sales
Collaboration With ENT Specialists and Allergy Clinics Strengthens Integrated Treatment Approaches
Surge in Home and Portable Air Quality Devices Propels Pollen Monitoring Integration
Focus on Rapid Allergen Diagnostic Testing and Home Kits Enhances Consumer Empowerment
Growth in Biologics and Monoclonal Antibody Therapy Expands Options for Severe Allergy Management
Advances in Allergen Mapping and Pollen Forecasting Drive Personalized Treatment Solutions
Expansion of Mobile Health and Allergy Management Apps Spurs Digital Health Adoption in Allergy Control
Participation in Regulatory Guidelines for Allergy Medication Labeling Strengthens Safety Profiles
Increasing Awareness of Cross-Reactivity and Food-Pollen Syndrome Drives Demand for Educational Resources
Entry Into Pediatric Allergy Management Market Enhances Age-Specific Treatment Accessibility
Rising Popularity of Nasal Filters, HEPA Masks, and Wearables Strengthens Non-Pharmacological Product Category
Investment in Botanical and Non-Corticosteroid Therapeutics Enhances Natural Remedy Pipeline
Expansion of Allergy Care in Emerging Markets Through E-Pharmacy and Telehealth Platforms Supports Access
Differentiation Through Symptom Tracker Integration and Adherence Tools Improves Chronic Case Outcomes
Global Climate Change Patterns Alter Pollen Seasons, Increasing Duration and Intensity of Allergic Episodes
FOCUS ON SELECT PLAYERS
AbbVie Inc.
Aimmune Therapeutics
Alcon Inc.
ALK-Abello A/S
Allergopharma
Allergy Therapeutics
ASIT Biotech SA
Bayer AG
Biomay AG
bioMerieux SA
Circassia Pharmaceuticals
DBV Technologies
Genentech Inc.
GlaxoSmithKline plc
HAL Allergy Group
HOB Biotech Group Corp Ltd
Johnson & Johnson
LETIPharma
Merck KGaA
Stallergenes Greer
For more information about this report visit https://www.researchandmarkets.com/r/sou31h
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Pollen Allergy Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Vietnam exports up as US tariff threat lingers
Vietnam's exports rose sharply last month, official figures showed Friday, as the communist country tries to negotiate relief from swingeing tariffs threatened by US President Donald Trump. May exports stood at $39.6 billion, according to data from the General Statistics Office, up 17 percent on the same period a year ago, while the year-to-date total reached $180.2 billion, 14 percent higher than in 2024. Vietnam, a major centre for global brands producing shoes and clothes, says it is making progress in talks with Washington to head off Trump's threatened 46 percent levy. The Southeast Asian manufacturing hub has the third-biggest trade surplus with the United States after China and Mexico, putting it in the firing line for Trump's "Liberation Day" global tariff blitz. Vietnam's overall import-export turnover stood at $78.6 billion in May, 15.5 percent higher than the same month last year. Imports were up by 14.1 percent year on year to stand at $39 billion in May. Processed industrial goods dominated exports, while imports were led by production materials. Despite the tariff uncertainty, the United States remained Vietnam's number one export market with $57 billion in the first five months of 2025 -- up from $44 billion over the same period a year ago. Vietnamese and US trade negotiators meeting in Paris this week agreed to step up the pace of their talks. Vietnam has signed several agreements to buy hundreds of millions of dollars' worth of agricultural products and other raw materials from the United States as it seeks to rebalance their trading partnership. Trump's real estate group also broke ground last month on a $1.5-billion luxury golf resort in Vietnam, while his son Eric Trump has been scouting locations for a potential tower project in Ho Chi Minh City, the country's southern business hub. tmh-pdw/sco Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
Tesla CEO Elon Musk says he will spend 'a lot less' on future political campaigns
Tesla CEO Elon Musk said he intends to significantly reduce his political spending in future campaigns, during an interview at the Qatar Economic Forum on Tuesday. Musk reportedly donated more than $250 million (€221 million) to support Donald Trump's 2024 presidential campaign. When asked whether he would match that level of spending in the 2026 midterm elections, Musk replied, 'I think, in terms of political spending, I'm going to do a lot less in the future.' He was offered the role of head of the Department of Government Efficiency (DOGE), assisting the president in cutting thousands of federal jobs. However, Musk's political involvement has drawn backlash towards Tesla, including protests and acts of vandalism targeting its showrooms. His support for far-right European parties has also proved controversial, contributing to a steep drop in Tesla's EV sales across the region. Speaking at a town hall in Wisconsin in March, Musk commented, 'It's costing me a lot to be in this job,' referring to his role as a special government employee. Trump had also signalled that Musk's government tenure may be drawing to a close. During Tesla's Q1 earnings call, Musk stated that the time he spends on DOGE would decrease 'significantly' from May onwards. On Tuesday, he reaffirmed that he would remain Tesla's CEO for at least the next five years. Tesla's share price rose 3.6% intraday before paring gains later in the session. The world's largest EV maker has seen its stock rebound more than 50% from a year-low in late April, helped by improving market sentiment abroad amid easing US-China trade tensions. President Trump's recent Middle East tour further boosted US tech stocks, as he secured deals worth over $1 trillion with three major Gulf states. Musk was among the business leaders accompanying Trump on the trip. However, Tesla's shares are still down 12% year-to-date as of the market close on 20 May. Asked about the decline in Tesla's sales, Musk downplayed the concern. 'It's already turned around,' he said, referring to the share price recovery. 'The stock wouldn't be trading near all-time highs if it was not.' While acknowledging that Europe remains Tesla's weakest market, Musk attributed the decline to multiple factors, including tariff shocks and soft EV demand. The company reported a 20% year-on-year decline in EV revenue worldwide in the first quarter. In April, Tesla's European sales continued to fall significantly year-on-year: down 46% in Germany, 62% in the UK, and by more than two-thirds in Denmark, the Netherlands, and Sweden. Nevertheless, Musk highlighted stronger performance in other regions, stating, 'The sales numbers at this point are strong.' Despite the headwinds, investor optimism remains focused on Tesla's upcoming Robotaxi programme. Musk confirmed on Tuesday, in an interview with CNBC, that Tesla will launch the fully autonomous vehicle services in Austin by the end of June, as originally planned. He added that Robotaxi will later expand to Los Angeles and San Francisco following its Austin debut. Musk had earlier stated that unsupervised Full Self-Driving (FSD) technology would roll out in California and Texas by June. The Austin launch will feature the Model Y fitted with a 'localised parameter set' optimised for the region. Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Nvidia's research boss claims the company's Chinese AI researchers are now writing programs for Huawei instead and is blaming the US chip exports
When you buy through links on our articles, Future and its syndication partners may earn a commission. Nvidia's been banging the drum against the United State's China chip export restrictions for a while now, but while it had previously highlighted this in broad terms, the company now seems to be getting more direct with its claims. According to a machine translation of a report from Taiwan Economic Daily (via Wccftech), Nvidia's chief scientist and senior VP of research, Bill Dally, claims that Huawei is scooping up ex-Nvidia AI researchers as a result of the restrictions. According to Dally, admittedly via a machine translation, the growth in the number of AI researchers working in China—apparently growing from a third of the world's researchers in 2019 to almost half of them today—has been forced by the US export restrictions. The idea is that without these restrictions, Huawei wouldn't be forced to lean so strongly into home-grown AI solutions, but now it must do so to keep up. Nvidia is clearly keen on presenting this argument (probably in hopes that the US administration specifically will hear it) to show that there are arguable downsides of banning its exports to China for the US. It certainly appeals to the ears of those concerned about the US-China technological arms race. As I said, though, the general argument isn't new—Nvidia has been touting it for a while. At Computex last month, Nvidia CEO Jensen Huang said: "AI researchers are still doing AI research in China" and "if they don't have enough Nvidia, they will use their own [chips]." And regarding Huawei specifically, Huang said the company has become "quite formidable". There is, of course, another reason other than US national interest that might make Nvidia keen to highlight possible negatives of export controls. Namely, the fact that these restrictions have cost and will cost the company lots of money. Nvidia itself has confirmed this, stating that after billions of dollars lost through restrictions of its H20 chips to China in Q1, it's expecting another $8 billion to be lost for the same reason in Q2. That's because Hopper, the company's previous chip architecture, "is no longer an option", according to the CEO. Huawei's latest Ascend 910 and 920 chips, courtesy of China's SMIC (Semiconductor Manufacturing International Corporation), will probably now be better options for Chinese AI companies than trying to get hands on Nvidia silicon somehow. And with ex-Nvidia researchers now apparently padding out the Chinese industry, who knows what will be cooked up next and when. Nvidia certainly seems to be presenting itself as worried about what's to come. The company can't complain about the vaguely 'poachy' aspect of this, though, really—not when Nvidia seems to be enticing likely TSMC employees in Taiwan with high salary job advertisements. Sometimes business is just business, you know? Best gaming PC: The top pre-built gaming laptop: Great devices for mobile gaming. Melden Sie sich an, um Ihr Portfolio aufzurufen.
